UK Scientists Develop Groundbreaking Vaccine to Prevent Bowel and Ovarian Cancer
‘Transformative’ new UK vaccine could prevent bowel and ovarian cancer in world first
Image: The Sun
A new vaccine developed by scientists from the University of Oxford and Moderna aims to prevent bowel and ovarian cancer in individuals with Lynch syndrome. The vaccine, utilizing mRNA technology, will undergo trials this summer to assess its effectiveness in training the immune system to combat pre-cancerous cells.
- 01The vaccine targets individuals with Lynch syndrome, an inherited condition affecting 1 in 300 people in England.
- 02Around 175,000 people in England have Lynch syndrome, but only 5% are aware of their condition.
- 03The vaccine aims to train the immune system to recognize and eliminate pre-cancerous cells, potentially reducing cancer risk.
- 04The initial trial, named Intercept-Lynch, will begin this summer, with a second phase expected to start in 2027.
- 05If successful, the vaccine could be adapted for other cancers beyond those associated with Lynch syndrome.
Advertisement
In-Article Ad
Scientists from the University of Oxford and Moderna have developed a pioneering vaccine designed to prevent bowel and ovarian cancer, specifically targeting individuals with Lynch syndrome. This condition, which affects approximately 1 in 300 people in England, significantly increases the risk of various cancers, including bowel and ovarian cancer. The vaccine, utilizing mRNA technology similar to that used in COVID-19 vaccines, aims to train the immune system to recognize and eliminate pre-cancerous cells. The initial trial, known as Intercept-Lynch, is set to launch this summer, with the first patient expected to receive the vaccine soon. Researchers will analyze immune responses to optimize dosage and safety. If effective, the vaccine could not only benefit those with Lynch syndrome but also be adapted for broader cancer prevention in the future. This innovative approach has the potential to transform cancer prevention strategies for at-risk populations, as emphasized by lead investigator Professor David Church.
Advertisement
In-Article Ad
The vaccine could significantly reduce cancer risk for individuals with Lynch syndrome, improving health outcomes for a vulnerable population.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of mRNA vaccines for cancer prevention?
Connecting to poll...
More about University of Oxford
Read the original article
Visit the source for the complete story.